Q2 26 EPS GAAP
$-0.21
BEAT +8.02%
Est. $-0.23
Q2 26 Revenue
$3.3M
BEAT +93.78%
Est. $1.7M
vs S&P Since Q2 26
+56.2%
BEATING MARKET
ALEC +55.3% vs S&P -1.0%
Market Reaction
Did ALEC Beat Earnings? Q2 2026 Results
Alector, Inc. Delivered a cleaner-than-expected second quarter for fiscal 2026, beating Wall Street on both the top and bottom lines and extending its GAAP EPS beat streak to six consecutive quarters. The neurodegenerative disease biotech posted a GA… Read more Alector, Inc. Delivered a cleaner-than-expected second quarter for fiscal 2026, beating Wall Street on both the top and bottom lines and extending its GAAP EPS beat streak to six consecutive quarters. The neurodegenerative disease biotech posted a GAAP net loss of $0.21 per share, coming in 8.02% ahead of the $0.23 consensus estimate, while revenue of $3.32 million more than doubled analyst expectations of $1.71 million, a 93.78% beat. The headline driver was a sharp pullback in operating costs, with total expenses falling to $27.71 million from $42.01 million a year ago as prior reductions in force compressed both R&D and G&A spending. Collaboration revenue itself declined 57.8% year over year to $3.32 million, reflecting lower recognition tied to the AL101 Alzheimer's program, and the stock continues to trade near its 52-week low with analysts carrying an average Hold rating. With $172.80 million in cash and investments on hand, management expects runway at least through 2027, and the company is targeting an IND submission for its lead ABC-platform antibody AL137 in Q1 2027, with first-in-human dosing in Australia no later than April 2027.
Key Takeaways
- • Significant reduction in operating expenses from prior reductions in force
- • Lower personnel-related costs driving R&D and G&A expense decreases
- • Decreased collaboration revenue from lower AL101 AD program recognition
ALEC Forward Guidance & Outlook
Management anticipates that cash, cash equivalents, and investments of $172.8 million as of June 30, 2026, will be sufficient to fund operations at least through 2027. The company is targeting an IND submission for AL137 in Q1 2027 and first-in-human dosing in Australia no later than April 2027. AL164 (modified tau siRNA) is advancing into IND-enabling studies. Earlier-stage siRNA programs targeting alpha-synuclein and NLRP3 are advancing toward lead candidate selection, with the company continuing to evaluate development plans and timing.
ALEC YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
ALEC Revenue by Segment
Business unit performance breakdown
“We continue to make steady progress across our ABC-enabled preclinical and research pipeline. Our work across antibodies, enzymes, and siRNA reflects the versatility of the ABC platform and our strategy to apply it to programs where enhanced brain delivery may address important limitations in the treatment of neurodegenerative diseases. We remain focused on disciplined execution as we advance our portfolio toward clinical development, with the goal of addressing important unmet needs for patients living with neurodegenerative diseases.”
— Arnon Rosenthal, Q2 2026 Earnings Press Release
ALEC Earnings Trends
ALEC vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ALEC EPS Trend
Earnings per share: estimate vs actual
ALEC Revenue Trend
Quarterly revenue: estimate vs actual
ALEC Quarterly Results
7 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.23 | $-0.21 | +8.02% | $3.3M | +93.78% |
| Q1 26 BEAT | $-0.28 | $-0.21 | +24.22% | $1.0M | -90.52% |
| Q4 25 BEAT FY | $-0.36 | $-0.34 | +6.41% | $6.2M | +218.63% |
| FY Full Year | $-1.38 | $-1.39 | -1.09% | $21.0M | +24.39% |
| Q3 25 BEAT | $-0.41 | $-0.34 | +17.66% | $3.3M | -6.52% |
| Q2 25 BEAT | $-0.47 | $-0.30 | +36.17% | $7.9M | +180.73% |
| Q1 25 BEAT | $-0.46 | $-0.41 | +10.87% | $3.7M | -13.55% |
| Q4 24 BEAT FY | $-0.54 | $-0.02 | +96.33% | $54.2M | +165.82% |
| FY Full Year | — | $-1.23 | — | $100.6M | — |